Navigation Links
FDA Panel Weighs Approving HPV Vaccine for Males
Date:9/9/2009

They can get variety of illnesses from the sexually transmitted virus, experts note

WEDNESDAY, Sept. 9 (HealthDay News) -- A U.S. health advisory committee on Wednesday will discuss whether or not to approve Gardasil, a vaccine that targets sexually transmitted human papillomavirus (HPV), for use in boys as well as girls.

Merck & Co., which makes the vaccine, has asked the U.S. Food and Drug Administration to approve Gardasil for males aged 9 to 26. It is already approved in females aged 9 and older to help prevent cervical cancer.

The FDA is not bound to follow the recommendations of its committees -- in this case the Vaccines and Related Biological Products Advisory Committee -- but it usually does. And while it's unclear how the committee will vote, a nod toward approving Gardasil for males would not be a huge surprise, experts said.

"It is really hard to get a read on these things, but I don't think anybody is going to be shocked if eventually this is extended to boys, especially since the science is pretty solid here," said Fred Wyand, a spokesman for the American Social Health Association, in Research Triangle Park, N.C.

"I would not be surprised at all if FDA approved the new indication," agreed Dr. Jonathan L. Temte, a professor of family medicine at the University of Wisconsin School of Medicine and Public Health in Madison.

Temte is also a voting member of the U.S. Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices (ACIP) and explained that if the FDA approves the new use for males, the CDC committee can expect to see the item on its agenda in October.

Health experts feel it makes sense to vaccinate boys against the virus, which causes genital warts in both males and females, cervical cancer in women and also penile and anal cancer in men (although these remain much rarer than cervical malignancies).

"We're supportive in general of giving vaccines to boys for a number of reasons," Wyand said. "Clinical trials have shown it's pretty effective -- 90 percent effective in preventing genital lesions [in boys]. Trials in a subset of gay men also found the vaccine to be effective in preventing external lesions, so the signs are pretty clear that it works in guys."

Vaccinating boys would help shield girls, too, the experts added. "It's a sexually transmitted disease, and it takes two people to transmit the virus," said Dr. Jay Brooks, chairman of hematology/oncology at Ochsner Health System in Baton Rouge, La. "If the vaccine can reduce the risk of infection in men as well as women, then I believe it should be given to both men and women."

But Gardasil has generated controversy, especially with some conservatives and parents' rights groups who contend the vaccine could promote premarital sex.

The committee will also be ruling on whether to approve a second HPV vaccine, GlaxoSmithKline's Cervarix, for girls and women aged 10 to 25. Studies have shown the vaccine prevents infection with HPV 93 percent of the time.

Gardasil, which was approved for girls in 2006, covers four types of HPV, two of which cause about 70 percent of cervical cancers worldwide.

Since its approval, Gardasil has proven to be safe and nearly 100 percent effective in preventing precancerous cervical lesions from the four HPV strains targeted by the vaccine, according to studies. However, there have been side effects reported that include fainting and blood clotting. Research published last month found that for every 100,000 doses of HPV vaccine distributed, there were 8.2 episodes of fainting and 0.2 episodes involving blood clotting.

Studies have also found that Gardasil is much more effective when given to girls or young women -- before they become sexually active.

"The reason you give this is to prevent disease and that's why we start at 11 or 12, before girls are sexually active," said Dr. Lolita McDavid, medical director of Child Advocacy and Protection at University Hospitals Case Medical Center in Cleveland. "About 10,000 American women will get cervical cancer in a year; about 3,700 are going to die from it."

"About 250,000 new case of genital warts appear in males every year," she added. "There certainly seems to be a benefit for males."

Experts hope that making the vaccine available for boys will have additional, non-medical benefits.

"Countless studies show that a lot of shame and stigma almost universally comes with any HPV diagnosis," Wyand said. "That's another factor that weighs into it. Hopefully, approving the vaccine for males would reduce any stigma."

More information

There's more on HPV at the U.S. Centers for Disease Control and Prevention.



SOURCES: Fred Wyand, spokesman, American Social Health Association, Research Triangle Park, N.C.; Jay Brooks, M.D., chairman, hematology/oncology, Ochsner Health System, Baton Rouge, La.; Lolita McDavid, M.D., medical director, Child Advocacy & Protection, University Hospitals Case Medical Center, Cleveland; Jonathan L. Temte, M.D., Ph.D., professor, family medicine, University of Wisconsin School of Medicine and Public Health, and voting member, Advisory Committee on Immunization Practices, CDC; briefing materials, U.S. Food and Drug Administration


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Cepheid Announces Accelerated Development of Flu A Panel Test
2. Arbitration Panel Finds in Favor of Tennessee Victim of Mariner Nursing Home Negligence
3. CBI Announces Multi-Stakeholder Collaboration Panel at Upcoming Effective Oncology Benefit Management Forum
4. Panel assesses evidence for the collection and use of family health history information
5. eDiets.com(R) Granted Continued Listing by NASDAQ Panel
6. The Elephant in the Room: Panel on Immigrations Impact on Health Care Reform
7. Bipartisan Panel of Industry, NGO and Academic Experts Proposes New Rules for Science in Federal Regulation
8. LG Electronics Introduces New Flat-Panel HDTVs Designed Specifically for Long-Term Care Facilities
9. First Midwest Healthcare Business Intelligence (BI) Summit October 27 in Minneapolis; International Panel to Discuss New Regulations, Recession, & BI Best Practices
10. Litepanels to Receive First-Ever Emmy Statue for Lighting Equipment Technology
11. CDC Panel to Recommend Who Should Get Swine Flu Shot
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
FDA Panel Weighs Approving HPV Vaccine for Males
(Date:12/2/2016)... ... December 02, 2016 , ... "Pro3rd Accents Volume 2 is a ... versatile lower third titles with just a few clicks of the mouse," said Christina ... 30 lower third animations. Choose from various styles with accented animations, rigid boxes, simplistic ...
(Date:12/2/2016)... ... December 02, 2016 , ... ... needy individuals and families from eight different sites throughout Miami-Dade and Broward counties. ... 1,000 volunteers worked very hard on Thanksgiving morning by putting together individual meals ...
(Date:12/2/2016)... Pass, OR (PRWEB) , ... December 02, 2016 ... ... Wein, Medical Technologist/Clinical Laboratory Scientist & Author of Type 2 Diabetes: The Owner’s ... host of The Sharon Kleyne Hour Power of Water, Global Climate Change and ...
(Date:11/30/2016)... ... 30, 2016 , ... The Fertility Centers of New ... Cigna Infertility Center of Excellence. The Cigna Center of Excellence recognizes participating infertility ... to be designated a Cigna Infertility Center of Excellence," said Fertility Centers of ...
(Date:11/30/2016)... , ... November 30, 2016 , ... "I hate when ... arm while brushing my teeth," said an inventor from Bridgewater, N.J. "I thought that ... develop this handy device." , He developed the patent-pending DEFLECTOR to prevent saliva and ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... 2016 Orthopedic Implants (Including Spinal Implants, ... to Gain a Significant Market Share Owing to a Large ... ... According to a new report by Persistence ... Packaging: Clamshell Product Type Segment Projected to Witness a Significantly ...
(Date:12/2/2016)... , Dec. 2, 2016   CytoSorbents Corporation ... commercializing its European Union approved CytoSorb ® cytokine ... surgery patients worldwide, announced that Dr. Phillip Chan ... 9th Annual LD Micro Main Event investor conference ... at the Luxe Sunset Boulevard Hotel in ...
(Date:12/2/2016)... On Thursday, the NASDAQ Composite ended the trading ... edged 0.36% higher, to finish at 19,191.93; and the S&P ... as six out of nine sectors ended the day in ... Services equities: Myriad Genetics Inc. (NASDAQ: MYGN ), ... Inc. (NASDAQ: INCR ), and La Quinta Holdings ...
Breaking Medicine Technology: